Recommendations for Cervical Cancer Prevention in Asia Pacific
Identifieur interne : 003192 ( PascalFrancis/Corpus ); précédent : 003191; suivant : 003193Recommendations for Cervical Cancer Prevention in Asia Pacific
Auteurs : Suzanne M. Garland ; Jack Cuzick ; Efren J. Domingo ; Sue J. Goldie ; Young-Tak Kim ; Ryo Konno ; D. Maxwell Parkin ; You-Lin Qiao ; Rengaswamy Sankaranarayanan ; Peter L. Stern ; SUN KUIE TAY ; F. Xavier BoschSource :
- Vaccine. Supplement [ 1359-5938 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Asia Oceania includes countries from both the Asia Pacific region and Australasia, which cover very diverse geographical areas and populations as well as bearing 52% of the cervical cancer burden in the world. Human papillomavirus (HPV) genotype distribution in women with normal cytology varies between countries in this region, as well as with the distribution typically observed in worldwide estimates or in Western countries. HPV-16 remains the predominant oncogenic type for high-grade cervical dysplasia and cervical cancer across the region, and HPV-18 is generally among the five most common types. HPV-58 is commonly found in cervical cancer as well as in women with normal cytology, and HPV-31, 33 and 35 are relatively less frequent in these regions compared to the West. While screening programmes have been proposed and implemented in several populations, successful programmes are rather limited and the majority of countries still have no or minimal screening services. Prophylactic HPV vaccination will only be feasible when it becomes affordable, thus the current priority and the short-term goal for cervical cancer control is to identify feasible and effective screening measures, and to find the most effective way to combine vaccination with sustainable screening programmes. This Regional Report has carefully described the disease burden of HPV and cervical cancer and the current situations in cervical cancer prevention for many countries in the Asia Oceania region. These data identify the many challenges and opportunities to be considered for policy decisions for cervical cancer control. Furthermore, this report presents the results of advanced decision analytic models calibrated to countries in the region that provide early insight into what strategies are most promising and those likely to be cost-effective and affordable. It thus provides a synthesis of the available evidence-based scientific information, in the context of a significant and systematic international review, that is likely to be useful to governments and public health providers.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 08-0525051 INIST |
|---|---|
| ET : | Recommendations for Cervical Cancer Prevention in Asia Pacific |
| AU : | GARLAND (Suzanne M.); CUZICK (Jack); DOMINGO (Efren J.); GOLDIE (Sue J.); KIM (Young-Tak); KONNO (Ryo); PARKIN (D. Maxwell); QIAO (You-Lin); SANKARANARAYANAN (Rengaswamy); STERN (Peter L.); SUN KUIE TAY; BOSCH (F. Xavier); BOSCH (F. Xavier) |
| AF : | Department of Microbiology and Infectious Diseases, The Royal Women's Hospital/Australie (1 aut.); Department of Obstetrics and Gynaecology, University of Melbourne/Melbourne, Victoria/Australie (1 aut.); Cancer Research UK Centre forEpidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine/London/Royaume-Uni (2 aut.); Department of Obstetrics and Gynecology, University of the Philippines College of Medicine -Philippine General Hospital/Manila/Philippines (3 aut.); Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health/Boston, MA/Etats-Unis (4 aut.); Department of Obstetrics and Gynecology, University of Ulsan, Asan Medical Center/Seoul/Corée, République de (5 aut.); Department of Gynecology, Jichi Medical University Saitama Medical Center/Omiya, Saitama/Japon (6 aut.); Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford/Oxford/Royaume-Uni (7 aut.); Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College/Chine (8 aut.); Screening Group, International Agency for Research on Cancer/Lyon/France (9 aut.); CR UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester/Manchester/Royaume-Uni (10 aut.); Gynaecologic Oncology Section, Department of Obstetrics & Gynaecology, Singapore General Hospital and National Cancer Centre Singapore/Singapour (11 aut.); Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia -Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona)/Espagne (12 aut.); Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology - Institut Català d'Oncologia (ICO), Avda. Gran Via s/n Km 2.7/08907 L'Hospitalet de Llobregat, Barcelona/Espagne (1 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Vaccine. Supplement; ISSN 1359-5938; Royaume-Uni; Da. 2008; Vol. 26; No. 12; M89-M98; Bibl. 35 ref. |
| LA : | Anglais |
| EA : | Asia Oceania includes countries from both the Asia Pacific region and Australasia, which cover very diverse geographical areas and populations as well as bearing 52% of the cervical cancer burden in the world. Human papillomavirus (HPV) genotype distribution in women with normal cytology varies between countries in this region, as well as with the distribution typically observed in worldwide estimates or in Western countries. HPV-16 remains the predominant oncogenic type for high-grade cervical dysplasia and cervical cancer across the region, and HPV-18 is generally among the five most common types. HPV-58 is commonly found in cervical cancer as well as in women with normal cytology, and HPV-31, 33 and 35 are relatively less frequent in these regions compared to the West. While screening programmes have been proposed and implemented in several populations, successful programmes are rather limited and the majority of countries still have no or minimal screening services. Prophylactic HPV vaccination will only be feasible when it becomes affordable, thus the current priority and the short-term goal for cervical cancer control is to identify feasible and effective screening measures, and to find the most effective way to combine vaccination with sustainable screening programmes. This Regional Report has carefully described the disease burden of HPV and cervical cancer and the current situations in cervical cancer prevention for many countries in the Asia Oceania region. These data identify the many challenges and opportunities to be considered for policy decisions for cervical cancer control. Furthermore, this report presents the results of advanced decision analytic models calibrated to countries in the region that provide early insight into what strategies are most promising and those likely to be cost-effective and affordable. It thus provides a synthesis of the available evidence-based scientific information, in the context of a significant and systematic international review, that is likely to be useful to governments and public health providers. |
| CC : | 002A05F04; 002B04 |
| FD : | Prévention; Asie; Australasie; Vaccination; Cancer du col de l'utérus |
| FG : | Océanie; Pathologie de l'appareil génital femelle; Pathologie du col de l'utérus; Tumeur maligne; Cancer |
| ED : | Prevention; Asia; Australasia; Vaccination; Cervical cancer |
| EG : | Oceania; Female genital diseases; Uterine cervix diseases; Malignant tumor; Cancer |
| SD : | Prevención; Asia; Australasia; Vacunación; Cáncer de cuello del útero |
| LO : | INIST-20289S.354000185329380090 |
| ID : | 08-0525051 |
Links to Exploration step
Pascal:08-0525051Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Recommendations for Cervical Cancer Prevention in Asia Pacific</title><author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M." last="Garland">Suzanne M. Garland</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Department of Obstetrics and Gynaecology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cuzick, Jack" sort="Cuzick, Jack" uniqKey="Cuzick J" first="Jack" last="Cuzick">Jack Cuzick</name><affiliation><inist:fA14 i1="03"><s1>Cancer Research UK Centre forEpidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Domingo, Efren J" sort="Domingo, Efren J" uniqKey="Domingo E" first="Efren J." last="Domingo">Efren J. Domingo</name><affiliation><inist:fA14 i1="04"><s1>Department of Obstetrics and Gynecology, University of the Philippines College of Medicine -Philippine General Hospital</s1><s2>Manila</s2><s3>PHL</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Goldie, Sue J" sort="Goldie, Sue J" uniqKey="Goldie S" first="Sue J." last="Goldie">Sue J. Goldie</name><affiliation><inist:fA14 i1="05"><s1>Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kim, Young Tak" sort="Kim, Young Tak" uniqKey="Kim Y" first="Young-Tak" last="Kim">Young-Tak Kim</name><affiliation><inist:fA14 i1="06"><s1>Department of Obstetrics and Gynecology, University of Ulsan, Asan Medical Center</s1><s2>Seoul</s2><s3>KOR</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Konno, Ryo" sort="Konno, Ryo" uniqKey="Konno R" first="Ryo" last="Konno">Ryo Konno</name><affiliation><inist:fA14 i1="07"><s1>Department of Gynecology, Jichi Medical University Saitama Medical Center</s1><s2>Omiya, Saitama</s2><s3>JPN</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Parkin, D Maxwell" sort="Parkin, D Maxwell" uniqKey="Parkin D" first="D. Maxwell" last="Parkin">D. Maxwell Parkin</name><affiliation><inist:fA14 i1="08"><s1>Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Qiao, You Lin" sort="Qiao, You Lin" uniqKey="Qiao Y" first="You-Lin" last="Qiao">You-Lin Qiao</name><affiliation><inist:fA14 i1="09"><s1>Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College</s1><s3>CHN</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sankaranarayanan, Rengaswamy" sort="Sankaranarayanan, Rengaswamy" uniqKey="Sankaranarayanan R" first="Rengaswamy" last="Sankaranarayanan">Rengaswamy Sankaranarayanan</name><affiliation><inist:fA14 i1="10"><s1>Screening Group, International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stern, Peter L" sort="Stern, Peter L" uniqKey="Stern P" first="Peter L." last="Stern">Peter L. Stern</name><affiliation><inist:fA14 i1="11"><s1>CR UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester</s1><s2>Manchester</s2><s3>GBR</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sun Kuie Tay" sort="Sun Kuie Tay" uniqKey="Sun Kuie Tay" last="Sun Kuie Tay">SUN KUIE TAY</name><affiliation><inist:fA14 i1="12"><s1>Gynaecologic Oncology Section, Department of Obstetrics & Gynaecology, Singapore General Hospital and National Cancer Centre Singapore</s1><s3>SGP</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F. Xavier" last="Bosch">F. Xavier Bosch</name><affiliation><inist:fA14 i1="13"><s1>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia -Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona)</s1><s3>ESP</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0525051</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0525051 INIST</idno><idno type="RBID">Pascal:08-0525051</idno><idno type="wicri:Area/PascalFrancis/Corpus">003192</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Recommendations for Cervical Cancer Prevention in Asia Pacific</title><author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M." last="Garland">Suzanne M. Garland</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Department of Obstetrics and Gynaecology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cuzick, Jack" sort="Cuzick, Jack" uniqKey="Cuzick J" first="Jack" last="Cuzick">Jack Cuzick</name><affiliation><inist:fA14 i1="03"><s1>Cancer Research UK Centre forEpidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Domingo, Efren J" sort="Domingo, Efren J" uniqKey="Domingo E" first="Efren J." last="Domingo">Efren J. Domingo</name><affiliation><inist:fA14 i1="04"><s1>Department of Obstetrics and Gynecology, University of the Philippines College of Medicine -Philippine General Hospital</s1><s2>Manila</s2><s3>PHL</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Goldie, Sue J" sort="Goldie, Sue J" uniqKey="Goldie S" first="Sue J." last="Goldie">Sue J. Goldie</name><affiliation><inist:fA14 i1="05"><s1>Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kim, Young Tak" sort="Kim, Young Tak" uniqKey="Kim Y" first="Young-Tak" last="Kim">Young-Tak Kim</name><affiliation><inist:fA14 i1="06"><s1>Department of Obstetrics and Gynecology, University of Ulsan, Asan Medical Center</s1><s2>Seoul</s2><s3>KOR</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Konno, Ryo" sort="Konno, Ryo" uniqKey="Konno R" first="Ryo" last="Konno">Ryo Konno</name><affiliation><inist:fA14 i1="07"><s1>Department of Gynecology, Jichi Medical University Saitama Medical Center</s1><s2>Omiya, Saitama</s2><s3>JPN</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Parkin, D Maxwell" sort="Parkin, D Maxwell" uniqKey="Parkin D" first="D. Maxwell" last="Parkin">D. Maxwell Parkin</name><affiliation><inist:fA14 i1="08"><s1>Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Qiao, You Lin" sort="Qiao, You Lin" uniqKey="Qiao Y" first="You-Lin" last="Qiao">You-Lin Qiao</name><affiliation><inist:fA14 i1="09"><s1>Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College</s1><s3>CHN</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sankaranarayanan, Rengaswamy" sort="Sankaranarayanan, Rengaswamy" uniqKey="Sankaranarayanan R" first="Rengaswamy" last="Sankaranarayanan">Rengaswamy Sankaranarayanan</name><affiliation><inist:fA14 i1="10"><s1>Screening Group, International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stern, Peter L" sort="Stern, Peter L" uniqKey="Stern P" first="Peter L." last="Stern">Peter L. Stern</name><affiliation><inist:fA14 i1="11"><s1>CR UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester</s1><s2>Manchester</s2><s3>GBR</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sun Kuie Tay" sort="Sun Kuie Tay" uniqKey="Sun Kuie Tay" last="Sun Kuie Tay">SUN KUIE TAY</name><affiliation><inist:fA14 i1="12"><s1>Gynaecologic Oncology Section, Department of Obstetrics & Gynaecology, Singapore General Hospital and National Cancer Centre Singapore</s1><s3>SGP</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F. Xavier" last="Bosch">F. Xavier Bosch</name><affiliation><inist:fA14 i1="13"><s1>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia -Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona)</s1><s3>ESP</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Vaccine. Supplement</title><title level="j" type="abbreviated">Vaccine., Suppl.</title><idno type="ISSN">1359-5938</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine. Supplement</title><title level="j" type="abbreviated">Vaccine., Suppl.</title><idno type="ISSN">1359-5938</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Asia</term><term>Australasia</term><term>Cervical cancer</term><term>Prevention</term><term>Vaccination</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Prévention</term><term>Asie</term><term>Australasie</term><term>Vaccination</term><term>Cancer du col de l'utérus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Asia Oceania includes countries from both the Asia Pacific region and Australasia, which cover very diverse geographical areas and populations as well as bearing 52% of the cervical cancer burden in the world. Human papillomavirus (HPV) genotype distribution in women with normal cytology varies between countries in this region, as well as with the distribution typically observed in worldwide estimates or in Western countries. HPV-16 remains the predominant oncogenic type for high-grade cervical dysplasia and cervical cancer across the region, and HPV-18 is generally among the five most common types. HPV-58 is commonly found in cervical cancer as well as in women with normal cytology, and HPV-31, 33 and 35 are relatively less frequent in these regions compared to the West. While screening programmes have been proposed and implemented in several populations, successful programmes are rather limited and the majority of countries still have no or minimal screening services. Prophylactic HPV vaccination will only be feasible when it becomes affordable, thus the current priority and the short-term goal for cervical cancer control is to identify feasible and effective screening measures, and to find the most effective way to combine vaccination with sustainable screening programmes. This Regional Report has carefully described the disease burden of HPV and cervical cancer and the current situations in cervical cancer prevention for many countries in the Asia Oceania region. These data identify the many challenges and opportunities to be considered for policy decisions for cervical cancer control. Furthermore, this report presents the results of advanced decision analytic models calibrated to countries in the region that provide early insight into what strategies are most promising and those likely to be cost-effective and affordable. It thus provides a synthesis of the available evidence-based scientific information, in the context of a significant and systematic international review, that is likely to be useful to governments and public health providers.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1359-5938</s0></fA01><fA03 i2="1"><s0>Vaccine., Suppl.</s0></fA03><fA05><s2>26</s2></fA05><fA06><s2>12</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Recommendations for Cervical Cancer Prevention in Asia Pacific</s1></fA08><fA09 i1="01" i2="1" l="ENG"><s1>Prevention of Cervical Cancer in the Asia Pacific Region: Progress and Challenges on HPV Vaccination and Screening</s1></fA09><fA11 i1="01" i2="1"><s1>GARLAND (Suzanne M.)</s1></fA11><fA11 i1="02" i2="1"><s1>CUZICK (Jack)</s1></fA11><fA11 i1="03" i2="1"><s1>DOMINGO (Efren J.)</s1></fA11><fA11 i1="04" i2="1"><s1>GOLDIE (Sue J.)</s1></fA11><fA11 i1="05" i2="1"><s1>KIM (Young-Tak)</s1></fA11><fA11 i1="06" i2="1"><s1>KONNO (Ryo)</s1></fA11><fA11 i1="07" i2="1"><s1>PARKIN (D. Maxwell)</s1></fA11><fA11 i1="08" i2="1"><s1>QIAO (You-Lin)</s1></fA11><fA11 i1="09" i2="1"><s1>SANKARANARAYANAN (Rengaswamy)</s1></fA11><fA11 i1="10" i2="1"><s1>STERN (Peter L.)</s1></fA11><fA11 i1="11" i2="1"><s1>SUN KUIE TAY</s1></fA11><fA11 i1="12" i2="1"><s1>BOSCH (F. Xavier)</s1></fA11><fA12 i1="01" i2="1"><s1>BOSCH (F. Xavier)</s1><s9>ed.</s9></fA12><fA14 i1="01"><s1>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Obstetrics and Gynaecology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>Cancer Research UK Centre forEpidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Obstetrics and Gynecology, University of the Philippines College of Medicine -Philippine General Hospital</s1><s2>Manila</s2><s3>PHL</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Obstetrics and Gynecology, University of Ulsan, Asan Medical Center</s1><s2>Seoul</s2><s3>KOR</s3><sZ>5 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Gynecology, Jichi Medical University Saitama Medical Center</s1><s2>Omiya, Saitama</s2><s3>JPN</s3><sZ>6 aut.</sZ></fA14><fA14 i1="08"><s1>Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3><sZ>7 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College</s1><s3>CHN</s3><sZ>8 aut.</sZ></fA14><fA14 i1="10"><s1>Screening Group, International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="11"><s1>CR UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester</s1><s2>Manchester</s2><s3>GBR</s3><sZ>10 aut.</sZ></fA14><fA14 i1="12"><s1>Gynaecologic Oncology Section, Department of Obstetrics & Gynaecology, Singapore General Hospital and National Cancer Centre Singapore</s1><s3>SGP</s3><sZ>11 aut.</sZ></fA14><fA14 i1="13"><s1>Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia -Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona)</s1><s3>ESP</s3><sZ>12 aut.</sZ></fA14><fA15 i1="01"><s1>Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology - Institut Català d'Oncologia (ICO), Avda. Gran Via s/n Km 2.7</s1><s2>08907 L'Hospitalet de Llobregat, Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ></fA15><fA20><s2>M89-M98</s2></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20289S</s2><s5>354000185329380090</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>35 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0525051</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Vaccine. Supplement</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Asia Oceania includes countries from both the Asia Pacific region and Australasia, which cover very diverse geographical areas and populations as well as bearing 52% of the cervical cancer burden in the world. Human papillomavirus (HPV) genotype distribution in women with normal cytology varies between countries in this region, as well as with the distribution typically observed in worldwide estimates or in Western countries. HPV-16 remains the predominant oncogenic type for high-grade cervical dysplasia and cervical cancer across the region, and HPV-18 is generally among the five most common types. HPV-58 is commonly found in cervical cancer as well as in women with normal cytology, and HPV-31, 33 and 35 are relatively less frequent in these regions compared to the West. While screening programmes have been proposed and implemented in several populations, successful programmes are rather limited and the majority of countries still have no or minimal screening services. Prophylactic HPV vaccination will only be feasible when it becomes affordable, thus the current priority and the short-term goal for cervical cancer control is to identify feasible and effective screening measures, and to find the most effective way to combine vaccination with sustainable screening programmes. This Regional Report has carefully described the disease burden of HPV and cervical cancer and the current situations in cervical cancer prevention for many countries in the Asia Oceania region. These data identify the many challenges and opportunities to be considered for policy decisions for cervical cancer control. Furthermore, this report presents the results of advanced decision analytic models calibrated to countries in the region that provide early insight into what strategies are most promising and those likely to be cost-effective and affordable. It thus provides a synthesis of the available evidence-based scientific information, in the context of a significant and systematic international review, that is likely to be useful to governments and public health providers.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05F04</s0></fC02><fC02 i1="02" i2="X"><s0>002B04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Prévention</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Prevention</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Prevención</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Asie</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Asia</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Asia</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Australasie</s0><s2>NG</s2><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Australasia</s0><s2>NG</s2><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Australasia</s0><s2>NG</s2><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Vaccination</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Vaccination</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Vacunación</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Cancer du col de l'utérus</s0><s2>NM</s2><s5>14</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Cervical cancer</s0><s2>NM</s2><s5>14</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Cáncer de cuello del útero</s0><s2>NM</s2><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Océanie</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Oceania</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Oceania</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil génital femelle</s0><s5>13</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Female genital diseases</s0><s5>13</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Aparato genital hembra patología</s0><s5>13</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du col de l'utérus</s0><s5>16</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Uterine cervix diseases</s0><s5>16</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Cuello útero patología</s0><s5>16</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>17</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>17</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>17</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fN21><s1>343</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 08-0525051 INIST</NO><ET>Recommendations for Cervical Cancer Prevention in Asia Pacific</ET><AU>GARLAND (Suzanne M.); CUZICK (Jack); DOMINGO (Efren J.); GOLDIE (Sue J.); KIM (Young-Tak); KONNO (Ryo); PARKIN (D. Maxwell); QIAO (You-Lin); SANKARANARAYANAN (Rengaswamy); STERN (Peter L.); SUN KUIE TAY; BOSCH (F. Xavier); BOSCH (F. Xavier)</AU><AF>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital/Australie (1 aut.); Department of Obstetrics and Gynaecology, University of Melbourne/Melbourne, Victoria/Australie (1 aut.); Cancer Research UK Centre forEpidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine/London/Royaume-Uni (2 aut.); Department of Obstetrics and Gynecology, University of the Philippines College of Medicine -Philippine General Hospital/Manila/Philippines (3 aut.); Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health/Boston, MA/Etats-Unis (4 aut.); Department of Obstetrics and Gynecology, University of Ulsan, Asan Medical Center/Seoul/Corée, République de (5 aut.); Department of Gynecology, Jichi Medical University Saitama Medical Center/Omiya, Saitama/Japon (6 aut.); Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford/Oxford/Royaume-Uni (7 aut.); Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College/Chine (8 aut.); Screening Group, International Agency for Research on Cancer/Lyon/France (9 aut.); CR UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester/Manchester/Royaume-Uni (10 aut.); Gynaecologic Oncology Section, Department of Obstetrics & Gynaecology, Singapore General Hospital and National Cancer Centre Singapore/Singapour (11 aut.); Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia -Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona)/Espagne (12 aut.); Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology - Institut Català d'Oncologia (ICO), Avda. Gran Via s/n Km 2.7/08907 L'Hospitalet de Llobregat, Barcelona/Espagne (1 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Vaccine. Supplement; ISSN 1359-5938; Royaume-Uni; Da. 2008; Vol. 26; No. 12; M89-M98; Bibl. 35 ref.</SO><LA>Anglais</LA><EA>Asia Oceania includes countries from both the Asia Pacific region and Australasia, which cover very diverse geographical areas and populations as well as bearing 52% of the cervical cancer burden in the world. Human papillomavirus (HPV) genotype distribution in women with normal cytology varies between countries in this region, as well as with the distribution typically observed in worldwide estimates or in Western countries. HPV-16 remains the predominant oncogenic type for high-grade cervical dysplasia and cervical cancer across the region, and HPV-18 is generally among the five most common types. HPV-58 is commonly found in cervical cancer as well as in women with normal cytology, and HPV-31, 33 and 35 are relatively less frequent in these regions compared to the West. While screening programmes have been proposed and implemented in several populations, successful programmes are rather limited and the majority of countries still have no or minimal screening services. Prophylactic HPV vaccination will only be feasible when it becomes affordable, thus the current priority and the short-term goal for cervical cancer control is to identify feasible and effective screening measures, and to find the most effective way to combine vaccination with sustainable screening programmes. This Regional Report has carefully described the disease burden of HPV and cervical cancer and the current situations in cervical cancer prevention for many countries in the Asia Oceania region. These data identify the many challenges and opportunities to be considered for policy decisions for cervical cancer control. Furthermore, this report presents the results of advanced decision analytic models calibrated to countries in the region that provide early insight into what strategies are most promising and those likely to be cost-effective and affordable. It thus provides a synthesis of the available evidence-based scientific information, in the context of a significant and systematic international review, that is likely to be useful to governments and public health providers.</EA><CC>002A05F04; 002B04</CC><FD>Prévention; Asie; Australasie; Vaccination; Cancer du col de l'utérus</FD><FG>Océanie; Pathologie de l'appareil génital femelle; Pathologie du col de l'utérus; Tumeur maligne; Cancer</FG><ED>Prevention; Asia; Australasia; Vaccination; Cervical cancer</ED><EG>Oceania; Female genital diseases; Uterine cervix diseases; Malignant tumor; Cancer</EG><SD>Prevención; Asia; Australasia; Vacunación; Cáncer de cuello del útero</SD><LO>INIST-20289S.354000185329380090</LO><ID>08-0525051</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003192 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003192 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:08-0525051
|texte= Recommendations for Cervical Cancer Prevention in Asia Pacific
}}
| This area was generated with Dilib version V0.6.33. |  |